Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy  by Moulton, Hong M. & Moulton, Jon D.
Biochimica et Biophysica Acta 1798 (2010) 2296–2303
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemReview
Morpholinos and their peptide conjugates: Therapeutic promise and challenge for
Duchenne muscular dystrophy
Hong M. Moulton a,⁎,1, Jon D. Moulton b,2,3
a Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA
b Gene Tools, LLC, 1001 Summerton Way, Philomath, OR 97370, USAAbbreviations: PMO, phosphodiamidate morpholino
intravenous; IP, intraperitoneal; IM, intramuscular; CK,
⁎ Corresponding author. Tel.: +1 541 908 0614.
E-mail addresses: hong.moulton@oregonstate.edu (H
1 Contribution: Conception, design, manuscript writin
2 Tel.: +1 541 929 7840x1201.
3 Contribution: Design, manuscript writing, ﬁnal appr
0005-2736/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbamem.2010.02.012a b s t r a c ta r t i c l e i n f oArticle history:
Received 16 December 2009
Received in revised form 3 February 2010
Accepted 7 February 2010
Available online 17 February 2010
Keyword:
Morpholino
PMO
Cell-penetrating peptide
Exon skipping
PPMO
Duchenne muscular dystrophyExon-skipping efﬁcacies of phosphodiamidate morpholino oligomers (PMOs) or the conjugates of PMOs with
cell-penetrating peptides (PPMOs) have been tested in various animal models of Duchenne muscular
dystrophy (DMD), including mdxmice, utrophin-dystrophin double-knockout mice, and CXMD dogs, as well
as in DMD patients in clinical trials. The studies have shown that PMOs can diffuse into leaky muscle cells,
modify splicing of DMD transcripts, induce expression of partially functional dystrophin, and improve
function of some skeletal muscles. PMOs are non-toxic, with a report of mdx mice tolerating a 3 g/kg dose,
and no drug-related safety issue in human has been reported. However, because of their poor cell uptake and
rapid renal clearance, large and frequently repeated doses of PMOs are likely required for functional beneﬁt
in some skeletal muscles of DMD patients. In addition, PMOs do not enter cardiomyocytes sufﬁciently to
relieve heart pathology, the efﬁcacy of delivery to various muscles varies greatly, and delivery across the
tissue of each skeletal muscle tissue is patchy. PPMOs enter cells at far lower doses, enter cardiomyocytes in
useful quantities, and deliver more evenly to myocytes both when different muscles are compared and when
assessed at the level of single muscle tissue sections. Compared to PMOs, far lower doses of PPMOs can
restore dystrophin sufﬁciently to reduce disease pathology, increase skeletal and cardiac muscle functions,
and prolong survival of animals. The biggest challenge for PPMO is determining safe and effective doses. The
toxicity of PPMOs will require caution when moving into the clinic. The ﬁrst PPMO-based DMD drug is
currently in preclinical development for DMD patients who can beneﬁt from skipping exon 50.oligomer; PPMO, cell-penetrating peptide conjugated P
creatine kinase
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1.1. Phosphodiamidate morpholino oligomers (PMOs)
Antisense oligos offer a promising therapeutic strategy for treatment
of the human genetic disease Duchenne muscular dystrophy (DMD).
Antisense oligos are used to bindwith RNA andmodify gene expression
by base-pairing to complementary base sequences. Phosphodiamidate
morpholinooligomers (PMOs) are uncharged antisensemolecules,with
structures analogous to nucleic acids but with the bases linked to an
unnatural backbone [1]. Each base is bound at the 2 position of a 6-
methylene morpholine ring, and the methylene is also bound to a
dimethylaminophosphorodiamidate group linked to the nitrogen of the
next morpholine ring (Fig. 1). PMOs are typically 18–30 bases in length.
They are stable in cells, and no enzyme is known to degrade them [2,3].
PMOshavebeenbroadly adoptedbydevelopmental biology researchers
to knockdown gene expression in embryos of model organisms such as
zebraﬁsh and Xenopus. Speciﬁcity and lack of immune response are
critical characteristics for oligos to be used in humans; the successful
and widespread use of PMOs for knockdowns in exquisitely sensitive
embryonic systems shows that they are a good choice for further testing
as human therapeutics [4–6].
PMOs regulate gene expression through a steric blocking mecha-
nism. Bound to complementary sequences of RNA, the PMOs get in the
way of processes that would normally take place at those sequences. By
selecting the appropriate target sequence, PMOs can get in the way of
proteins or snRNPs involved in splicing of pre-mRNA and this can be
exploited to redirect splicing. Most commonly, splice modiﬁcation
results in exclusion of an exon from the mature mRNA. A forefront
clinical application of PMOs is as a splicing modulator for treatment of
Duchenne muscular dystrophy (DMD).Fig. 1. Chemical structures of PMO (left) and the (RXRRBR)2-PMO (right). X = 6-
aminohexanoic acid and B = beta-alanine.1.2. Duchenne muscular dystrophy
DMD is a disabling, progressive, and deadly X-linked disease that
affects 1 in 3500–6000malebirths [7]. Symptomsusually appear in boys
aged 1 to 6, and most boys are conﬁned to a wheelchair at 12 years old
and die as early as teenage. Respiratory complications and heart failure
are commoncauses of death. There is noeffective treatment today. DMD
is caused by deﬁciency of dystrophin, a vital part of a protein complex
that connects the cytoskeleton of a muscle ﬁber to the surrounding
extracellular proteinmatrix through the cellmembrane. The dystrophin
deﬁciency is caused bymutations in the human dystrophin gene (DMD)
[8], a very large and mutation-prone gene, comprised of 79 exons.
Common mutations causing DMD are deletions, insertions, and
nonsense mutations. Deletions or insertions of numbers of protein-
coding bases that are not evenly divisible by three cause downstream
sequence to be frameshifted during translation.
Sometimes, deletion of an exon can stabilize a DMD transcript by
removing amutant stop codonwith the exonor by restoring the reading
frame of the downstream protein-coding sequence. The resulting
transcript contains an internal deletion but might still encode a
functional form of dystrophin. Internal in-frame deletions in DMD
occur naturally, giving rise to populations with milder allelic forms of
muscular dystrophy including Becker muscular dystrophy [7]. Becker
muscular dystrophy (BMD) affects 1 in 20,000 men, causing muscle
wasting. However, these patients experience a less severe phenotype
than theDMDpatients, ranging frommild tomoderately severe [9],with
life spans ranging fromnearly normal to deaths in their forties. Unlike in
DMDpatientswhohave undetectable or very low amount of dystrophin
(b5%ofwild type), protein ismore readily detectable inBMDpatientsby
Western blot although the size and amount vary among BMD patients.
The amount of dystrophin has been correlated to the severity of
phenotype, with N20% of wild-type concentration occurring with mild
phenotypes and 10–20% occurring with moderate phenotypes [9].
Molecular analysis of nucleic acids revealed that themajority of theBMD
patients have in-framemutations; the resulting dystrophin proteins are
semi-functional [10,11].
A strategy for the treatment of DMD is to turn the severe DMD
phenotype into mild to moderate BMD phenotype by removing the
exon(s) that disrupt the reading frame, producing internally truncated
but semi-functional dystrophin protein [12,13]. A PMO can be targeted
to an RNA sequence involved in splicing in order to force deletion of an
exon. Splice-modifying PMOs have been shown to induce expression of
modiﬁed forms of dystrophin in mice [14], dogs [15] and humans [16].
The conjugates of PMOs with cell-penetrating peptides (CPPs) have
been show to effectively restore dystrophin in dystrophic mice [17–19]
and cause targeted exon skipping in monkeys [20]. One of the peptide–
PMO conjugates (PPMOs, Fig. 1) is in preclinical development for
treatment of DMDpatients who can beneﬁt from skipping exon 50 [20].
In this article, we will ﬁrst review the DMD studies with PMO and
PPMOchemistries, focusing on systemic use of thesemolecules.Wewill
then discuss thepromises and challenges of PMOandPPMOchemistries
as DMD therapeutics.
2. PMO for DMD
2.1. Systemic delivery of PMOE23 in the mdx mouse model
mdx Mice carry a mutation in dystrophin exon 23 introducing a
stop codon. The mice have undetectable levels of dystrophin besides a
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staining. The dystrophin band is totally absent on an immune blot.
Lack of dystrophin causes many downstream effects, including (1)
leaking of muscle cell membranes, evaluated by elevated serum
creatine kinase (CK) and uptake of normally cell-impermeable dyes
and antibodies; (2) changes in cellular architecture including absence
of proteins in the dystrophin-associated protein complex; (3)
regeneration and degeneration of muscle ﬁbers, evaluated by the
ﬁber sizes and the location of nuclei; and (4) decreased muscle
functions, evaluated by grip strength, treadmill running, etc. Skipping
exon 23 maintains the reading frame of downstream sequence,
allowing expression of an in-frame protein product with the
polypeptide moiety encoded by exon 23 deleted. A 25-base PMO
sequence complementary to the splice donor site, the e23i23 junction
(PMOE23), has been used by several groups and showed various
degrees of efﬁcacy with different dose regimens [14,21,22].
Lu and colleagues were ﬁrst to demonstrate the systemic utility of
PMOE23. PMOE23was administered at 100 mg/kg to 6-week-oldmdx
mice by tail vein injection [14]. Single doses, three doses at weekly
intervals, and seven doses at weekly intervals were tested, and mice
were sacriﬁced 2 weeks after their ﬁnal doses. All dosing schedules
resulted in increased indicators for targeted exon skipping and new
dystrophin expression in skeletal muscles: increased exon-23-
skipped RNA (assayed by RT-PCR), increased dystrophin (assayed by
Western blots), and an increase in the number of ﬁbers visibly stained
for dystrophin (assayed by immunohistochemistry). These indicators
increased with the number of injections. Among the nine muscle
types evaluated, the exon-skipping effect of the PMOE23 is more
prominent in quadriceps, abdominals, intercostals, and gastrocnemii;
less prominent in diaphragm, biceps, triceps, and tibialis anterior
(TA); and absent in heart. Compared to wild-type concentration of
dystrophin transcript, exon-23-skipped RNA transcript at about 50%
concentration was detected in gastrocnemii, quadriceps, and abdom-
inal and intercostal muscles after seven injections.
Western blots revealed up to 5% of normal dystrophin concentra-
tion in intercostals and quadriceps after a single injection; about 20%
of normal levels in quadriceps, intercostals, and abdominal muscles
after three injections; and up to 50% of normal levels in gastrocnemii
and quadriceps after seven injections. A dystrophin protein band was
barely detected from the diaphragm and totally absent from the heart.
Immunoﬂuorescent staining of muscle sections revealed that the
fraction of ﬁbers staining positive for dystrophin increased with dose
and the intensity of the dystrophin signal became more evenly
distributed as the dose increased; however, even after seven
injections, the muscle sections appeared mottled with areas of high
and low staining, obvious when compared with the even staining of
healthy control sections. The 7 weekly PMO treatments resulted in
reduction of the serum CK levels and increased tetanic force of the
tibialis anterior muscle.
Comparison of single injections versus repeated injections at lower
doses shows that while the repeated lower doses restored dystrophin
expression more evenly across the muscle sections, the number of
centrally located nuclei was reduced more effectively by single larger
doses. Apparently, while the repeated low doses reachedmore cells, the
higher dose is needed to deliver sufﬁcient oligo to rearrange the cell
morphology [15,22]. This study showed that expression of sufﬁcient
dystrophin to enable detection by immunohistochemistry does not
prove that there is enough dystrophin to ameliorate cellular pathology,
and while increases in the count of ﬁbers staining for dystrophin may
present information about evenness of uptake into cells, it is not
sufﬁcient information to predict therapeutically useful doses of oligo.
2.2. Systemic delivery of PMOs in the CXMD dog model
Dogs carrying a mutation that is a model of Duchenne muscular
dystrophy, canine X-linked muscular dystrophy (CXMD) beagles,were treated systemically by IV infusion with PMOs. The CXMD
mutation causes exon 7 to be skipped, causing frameshift of
downstream sequence, which brings a premature stop codon in-
frame. The reading frame can be restored by skipping exons 6 and 8. A
cocktail of three oligos was found effective in vivo; these oligos
targeted an exonic site in exon 6, the splice donor site of exon 6, and
an exonic site in exon 8. The cocktail also caused some excision of
exon 9. Whether only exons 6 and 8 or all of exons 6, 8 and 9 were
excised from the CXMD transcripts, the RNA was translated to an in-
frame protein product with an internal peptide sequence deleted [15].
Systemic exon-skipping PMO treatmentwas tested on three CXMD
dogs, ranging from 2 to 5 months old. PMO cocktail solution was
injected through a 22-gauge catheter into the saphenous vein. Various
dose regimens were tested, with equimolar doses of all three
sequences in injections ranging from 26 to 62 ml. The 5-month-old
dog was injected weekly ﬁve times at 120 mg/kg (40 mg/kg each
sequence). One of the 2-month-old dogswas injected biweekly eleven
times at 120 mg/kg, and the other 2-month-old dog was injected
weekly seven times at 200 mg/kg (66 mg/kg each sequence). Dogs
were sacriﬁced 2 weeks after the ﬁnal injection.
New dystrophin expression was found by immunoﬂuorescence in
all skeletal muscles assessed. However, the amount of dystrophin
expression varied, with immunoblots showing dystrophin ranging
from trace to 50% of normal concentrations. In skeletal muscles,
amount of dystrophin expression was not correlated with ﬁber type
and contralateral muscles often differed in dystrophin level. Similar to
the mouse study, the exon-skipping efﬁciency of the PMOs varied by
muscles types. The dog given seven weekly treatments of 200 mg/kg
had the highest dystrophin levels, with dystrophin restored to 26% of
the wild-type level in three out of the eight skeletal muscles analyzed.
Increased dystrophin was detected in small patchy areas of the heart
by immunoﬂuorescence but was not detected by Western blot.
Some improvement in muscle function was observed for these
dogs. The treated dogs ran faster than their littermates. Muscle
inﬂammation and CK levels were reduced, indicating reduction in
disease pathology.
2.3. Intramuscular injection of AVI-4658 in humans
AVI-4658 is a PMO targeted to skip exon 51 of the human
dystrophin gene and is currently in a clinical trial for systemic
treatment of DMD (NCT00844597). Results of a previous trial
(NCT00159250), involving local injections of AVI-4658, have been
published [16]. In that trial, seven DMD boys were treated. Each
patient had a deletion somewhere upstream of exon 50 and extending
into or across exon 50; in each case skipping exon 51 was predicted to
restore the reading frame. The patients received intramuscular (IM)
injections in the extensor digitorum brevis (EDB) of their feet, with
AVI-4658 into one foot and the saline vehicle control into another foot.
Two patients received AVI-4658 at 0.09 mg, and ﬁve patients received
0.9 mg, in each case dissolved in 900 μl saline. The ﬁrst ﬁve patients
(two at low dose, three at high dose) were treated once each with
nine injections of 100 μl per injection, administered simultaneously in
a 1-cm2 grid using a 22-gaugemultiple needle array. The remaining two
patientswere treated oncewith four 225 μl injections simultaneously in
a 1-cm2 grid using a similar needle array. The muscles were biopsied
between 3 and 4 weeks post-injection, with most of the EDB removed.
Exon skipping was qualitatively detected by RT-PCR and Western
blot. RT-PCR products at the mass expected for successful skipping of
exon 51 were detected in treated muscles of all seven patients.
Western blots showed some new dystrophin protein expression.
Some ﬁbers in the biopsy section appeared dystrophin-positive, and
others appeared dystrophin-negative, so it was decided that quanti-
tation should rely on a ﬁber-by-ﬁber count of dystrophin signal
instead of the “averaged” quantity that would result from Western
blot or qRT-PCR of batches of cells.
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expression was based on immunohistochemical staining of muscle
ﬁbers and assessment of the ﬂuorescence of the stained ﬁbers.
Distribution of the dystrophin within the muscle ﬁbers was also
observed, with the dystrophin signal in high-dose treated muscles
appearing localized at the sarcolemma as it is in normal (wild-type)
muscle. Muscles treated with AVI-4658 were compared with saline-
treated control muscles and normal muscle to determine the percent
restoration of dystrophin in the treated muscle. Fluorescent signals
were normalized to signals from a β-spectrin antibody.
The signal from normal (wild-type) ﬁbers was taken as 100% signal
intensity. In the sections from the patient whose muscles produced
the brightest staining, the bright dystrophin-positive ﬁbers averaged
42% of the dystrophin signal intensity of wild-typemuscle ﬁbers while
dim ﬁbers averaged 11% of wild type. Across the population of high-
dose patients, the average dystrophin intensity was 26.4%. The
dystrophin signal of the treated muscle sections was fairly uneven,
with unstained or poorly stained ﬁbers visible in many samples.
Among the ﬁve high-dose patients, between 44% and 79% of the ﬁbers
were counted as dystrophin-positive. Though these patients under-
went local injections, most of the published immunostained images of
PMO-treated human DMDmuscle sections show patchiness of muscle
ﬁber staining, similar to the images from the muscles of the mouse
and dog DMD models after systemic PMO treatment.
While immunoﬂuorescent signals can indicate concentration
trends, the dystrophin intensities from immunohistochemistry do
not necessarily correlate with absolute dystrophin concentrations, as
factors such as variations in thickness of tissue slice, ﬂuorescence
quenching at high ﬂuorochrome concentrations, and nonlinearity of
detector sensitivity can cause estimates of concentration by immu-
noﬂuorescence vs. measurements by Western blot to yield differing
results.
3. CPPs-mediated systemic delivery of PMOs for DMD
Published to date, ﬁve different peptides each conjugated to
PMOE23 have been tested for their systemic utility for treatment of
DMD in mouse models and one of them, (RXRRBR)2, conjugated to a
PMO targeted to exon 50, has been tested in healthy monkeys.
3.1. (RXR)4 Peptide
The ﬁrst delivery moiety tested in mdx mouse model was the
(RXR)4 peptide where X=6-aminohexanoic acid. Its PMO conjugate,
PPMOE23, was ﬁrst administrated through the intraperitoneal (IP)
route [23]. Effects of the PPMO dose levels and the age of animals on
exon skipping were determined. Animals started treatment with the
same dose at 1 day, 4 weeks, or 1 year of age. While splice-modiﬁed
dystrophin expression increased for all ages treated, treatment at
younger age was clearly more beneﬁcial as the older animals had
more established pathology. A single-dose study in neonatal mice was
done to determine the dose and activity relationshipwith the PPMO at
1, 2, 5, 10, and 25 mg/kg. Immunoﬂuorescent detection of dystrophin
clearly showed a dose-dependent relationship, with higher levels of
dystrophin restoration observed at higher doses. Four doses of the
PPMO at a lower dose, 5 mg/kg per dose, administrated once a week
for 4 weeks led to near normal levels of dystrophin in diaphragms at
6 weeks of age. The PPMO effect was more modest in the tibialis
anterior (TA), gluteus maximus, and triceps brachialis; weak in the
colon and stomach; and absent in the heart. At 22 weeks after the
fourth injection, dystrophin was still detected in the diaphragm but
was discontinuous with some disruption of muscle architecture.
Peptide-related toxicity was not observed in the 5 mg/kg dose
regimen.
In another study, the same PPMOwas IV injected tomdxmice [19].
Effect of dose regimen on dystrophin restorationwas determined in 6-to 8-week-old mdx mice. PPMO was injected once at 25 mg/kg into
the tail vein. Widespread, uniform expression of dystrophin protein
over multiple tissue sections within seven muscle types was detected
in hind limb, fore limb, abdominal wall, and diaphragm muscles and,
importantly, in cardiac muscle. RT-PCR analysis showed nearly total
exon skipping of the mutated RNA transcript in the skeletal muscles
and 50% skipping in heart. Analysis of the muscles by immunoblotting
indicated that dystrophin was restored at 25–100% of wild-type levels
in skeletal muscles and at 10–20% of wild-type level in cardiac muscle.
The muscle pathology was decreased and function improved as
indicated by reduction of CK, detection of several proteins associated
with the dystrophin-associated protein complex (DAPC), and en-
hanced grip strength. Threeweekly IV injections of the PPMO at 6 mg/
kg also induced exon skipping in these muscles, but this dose regimen
was less effective, especially in heart, than the single 25 mg/kg dose.
The PPMO was further tested in the double-knockout (dKO) mouse
model that lacks both dystrophin andutrophin. Themice carry the same
mutation at exon 23 as the mdx mice in addition to another mutation
disabling utrophin. Unlike mdx mice that have near normal life span
with an average survival of 18 months, the dKO mice have an average
survival of 8.2 weeks with much more severe and progressive
dystrophic phenotypes including abnormal waddling gait, contracted
and stiff limbs, very pronounced kyphosis, and limited mobility. dKO
micemaybe amore appropriatemodel todetermine theeffectiveness of
the potential of DMD therapeutics. Two dose levels of the PPMO were
tested by IP route of administration. The higher dose at 25 mg/kg/week
for 6 weeks startedat10 days of age. Treatedmiceappearedhealthy and
survived until they were sacriﬁced for analysis at 13 weeks of age,
6 weeks after the last injection [24]. This survival duration was never
seen in untreated dKO mice. Dystrophic phenotypes were signiﬁcantly
improved. Both RT-PCR and Western analysis showed nearly complete
exon skipping andwild-type level of dystrophin in diaphragm and high
levels in other skeletal muscles but much less in the cardiac muscles.
Dystrophin distribution was uniformly detected in the ﬁbers of all
analyzed muscles except for cardiac muscles. However, the lower dose
at 5 mg/kg was not sufﬁcient to rescue the severe pathology of the dKO
mice; treatedmice exhibited no improvement in dystrophic phenotype
and survival.
3.2. (RXRRBR)2 Peptide
This is an analog of the (RXR)4 peptide with two of the 6-
aminohexanoic acid residues replaced with β-alanine. This peptide
was found to be less toxic to cells than the parent (RXR)4 peptide [25].
The utility of this peptide to deliver PMOs has been tested in mdx
mice, in wild-typemice, and in non-human primates. Batteries of tests
for exon-skipping efﬁciency were performed as was done for the
(RXR)4 PPMO. The sequence speciﬁcity of (RXRRBR)2-PMOE23 was
investigated in mdx mice as well as its utility to improve cardiac
function.
A single IV injection through a retro-orbital (RO) route of the
PPMO at 30 mg/kg resulted in production of exon-skipped transcript
accounting for N80% of dystrophin RT-PCR product in all skeletal
muscles and accounting for 50% in the cardiac muscle. The amount of
dystrophin protein restored in the skeletal muscles was near the
normal level in the TA of a wild-type mouse. Every skeletal muscle
ﬁber and 94% of cardiac muscle ﬁbers stained positive for dystrophin.
Six biweekly treatments over 3 months led to even higher amounts of
exon-skipped dystrophin mRNA and protein. In addition, the
dystrophin protein was detected in smooth muscles of large blood
vessels, the pulmonary artery, and the small intestine. Leaky cell
membranes were repaired as demonstrated by lack of uptake of
Evan's blue dye and mouse IgG. The same peptide conjugated to a
PMO with scrambled sequence was used as a control; when tested in
mdx mice, it did not cause exon skipping. Toxicity and immune
response were assayed for but not observed [17].
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employed a hemodynamic model [17]. Eight mdx mice were treated
twice with the PPMO at 30 mg/kg with a 2-week interval. Three weeks
after the second treatment, the PPMO-treatedmdxmice, untreatedmdx
mice, and the wild-type mice were challenged with dobutamine, a ß-
adrenergic stimulant that can increase cardiacworkload andmagnify the
dysfunctions of the heart ofmdxmice. All 10wild-typemice and all eight
PPMO-treated mdx mice survived the challenge, while only 3 of 9
untreated mdx mice survived the challenge. In addition, the cardiac
parameters, including end-diastolic volume, end-systolic pressure, dp/
dtmax, and cardiac pressure/volume loops of PPMO-treated mdx mice
were similar to the wild-type mice. The untreated mdx mice had
signiﬁcantly different values, indicating cardiac dysfunction.
Improvement of heart function by PPMO treatment was later
demonstrated in another study without using the hemodynamic
model [26]. This study demonstrated the long-term beneﬁt of PPMO
treatment prior to the development of cardiomyopathy. The effect of
the PPMO was investigated by treating 16-week-old mdx mice, the
age just before the development of cardiomyopathy in mdxmice. The
PPMO conjugate was injected IV at 12 mg/kg in two cycles of four
once-daily injections with a 2-week interval. A sham PPMO targeted
to an intron of the unrelated human β-globin gene was used as the
control. Cardiac CK-MB, a hallmark for cardiomyopathy, was signif-
icantly reduced, reaching wild-type concentration 5 weeks after the
ﬁrst injection. Dystrophin restoration was found throughout the heart
of treatedmdxmice. Dystrophin correctly localized at the sarcolemma
of cardiac muscles and its concentration as measured byWestern blot
was about 30% of wild-type level. No detectable dystrophin
expression was observed in sham-treated mdx mice.
Restoration of dystrophin prevented cardiac hypertrophy compared
to the sham-treatedmdxmice asmeasuredby signiﬁcant reduction in the
thickness of anterior and posterior walls in diastole and systole, total
heart mass, and left ventricle mass to body mass ratio. In addition, the
PPMO treatment prevented the mdx age-associated development
of diastolic dysfunction as shown by improvement in the E and A
waveforms from Doppler echocardiography compared to the sham-
treated mice. The same PPMO treatment was applied to a group of
8-week-old mdx mice with saline-treated mdx mice as the control.
Seven months after the treatment, the effect of PPMO relieving cardiac
hypertrophy was still detectable as indicated by lower left ventricle
mass to body mass ratio and thinner anterior and posterior walls
compared to the sham-treatedmice. Although dystrophin level was not
determined for this time point, it is expected that dystrophin is not
detectable 7 months after the treatment. An earlier studywith one cycle
of four once daily injections showed that dystrophin persisted in the
hearts of mdx mice for about 11 weeks after dosing [27]. The 7-month
study showed that even after dystrophin no longer persists in the heart,
earlier PPMO intervention can potentially reduce cardiomyopathy.
AVI-5038 is a (RXRRBR)2 peptide-conjugated PMO targeted to skip
human exon 50. This PPMO is currently in preclinical development for
DMD patients who can beneﬁt from the removal of exon 50. Initial
efﬁcacy of the PPMO has been demonstrated in healthy cynomolgus
monkey. With once-weekly IV injection for 4 weeks at 9 mg/kg, the
PPMO induced an average of 40%, 25%, and 2% exon-skipped product in
diaphragm, quadriceps, and heart (respectively) of four monkeys [20].
The level of exon skipping is probably an underestimate because in a
healthy monkey, the exon-skipped product is out of frame and
undergoes nonsense-mediated decay. With the same dose schedule at
a lower dose of 3 mg/kg, little exon-skipped product was detected,
similar to the saline-treated monkeys.
3.3. ASSLNIAX and (RXRRBR)2/ASSLNIAX chimeric peptides
Despite PPMOs' efﬁcacy in the muscles as demonstrated above, the
majorityof (RXR)4PPMO innormalmice [28] or (RXRRBR)2PPMO inmdx
mice (manuscript in preparation) were detected in livers and kidneys,with relative small amounts taken up by muscles. Using a muscle-
targeting ligand may increase muscle uptake of a PMO. ASSLNIAX was
identiﬁed as amuscle-speciﬁc peptide (MSP) by phage display screening
of a peptide library [29]. Phage carrying this peptide had a higher
selectivity for muscles than for the liver, kidney, or brain. The MSP–PMO
conjugate, tested inmdxmice, was found to have activity slightly higher
than PMO, but much lower than the (RXRRBR)2 PPMO [18]. These data
are not unexpected as the MSP may direct more PMO to muscles but it
lacks the “cell-penetrating” moiety of the (RXRRBR)2 peptide so very
little PMO was available for the RNA target in the cytosol/nuclei of cells.
However, tissue distribution analysis showed that the kidney and liver of
mice are still two major organs targeted by the MSP–PMO conjugate
(data not shown), suggesting that the selectivity of the MSP peptide is
signiﬁcantly reduced when it carries a PMO cargo.
Two chimeric peptides with MSP and (RXRRBR)2 combinations
were designed to assess the position and effect of MSP on the exon-
skipping efﬁcacy of the PPMO. MSP-(RXRRBR)2-PMO construct had
the cell-penetrating peptide positioned between the MSP and the
PMO. This construct was less effective than the parent PPMO,
(RXRRBR)2-PMO, as demonstrated by immunoﬂuoresecence,Western
blot, and RT-PCR assays. The second construct, (RXRRBR)2-MSP–PMO,
had the MSP positioned between the CPP and the PMO. This construct
gave 2- to 5-fold (depending on the tissue type) higher exon-skipping
activity in the skeletal muscles with no improvement in cardiac
muscles compared to (RXRRBR)2-PMO. Tissue distribution analysis
showed that there was little improvement of muscle selectivity with
either of the chimeric peptides and the majority of the materials were
still found in kidneys followed by livers (data not shown). Reduced
activity of the ﬁrst construct is likely caused by decreased internal-
ization of the conjugate, probably because the position of the MSP
inhibited the interaction of the CPP with cell membranes. Despite lack
of evidence for its intended muscle selectivity, the (RXRRBR)2-MSP–
PMO improved exon-skipping efﬁcacy over the parent PPMO, which
may reduce the therapeutic dose and dose frequency for treatment of
DMD [18].
4. Discussion and conclusion
4.1. PMO: promise and challenge for DMD
The systemic utility of PMO chemistry for the treatment of DMD
has been demonstrated in mice and dogs without safety issues. The
AVI-4658 intramuscular trial provided a proof-of-principle efﬁcacy
study in human. A systemic trial of AVI-4658 PMO in humans is
currently ongoing, and the data should be available in 2010. At the
time of this article, PMO targeted to exon 51 has been dosed in
humans up to 20 mg/kg once a week for 12 weeks and so far there are
no drug-related safety issues. Mouse dosed up to 3 g/kg of the
PMOE23 had no toxicity problem [30].
However, there are several issues that pose challenges for the use
of PMOs as effective and affordable drugs for DMD. The ﬁrst problem
with a PMO is its poor cellular uptake and rapid renal clearance from
circulation, so large and repeated doses are expected to be required
for therapeutic efﬁcacy. In mouse, 100 mg/kg per week for 7 weeks
was required for limited functional improvement. In dogs, the doses
resulting in functional beneﬁt were 120–200 mg/kg; dystrophin was
restored to 26% of the wild-type level at a dose of 200 mg/kg/week
through 7 weeks of injections. Most studies to date suggest that at
minimum, 10% to 20% of normal dystrophin levels is needed to
improve muscle function [9,31,32]. That large doses are required in
both animal models suggest that a dose near the 100 mg/kg per dose
may be required for humans to have some functional beneﬁt. One
could argue that the dose scaling from animal to human is by body
surface area so the human equivalent dose would be about 8 mg/kg
(1/12 of 100 mg/kg based on the difference in body surface area
between mice and human). However, there is no dose-scaling effect
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difference in body surface area between mouse and dog [14,15]. Dose
scaling across species by mass instead of by body surface area has
been shown for other antisense oligos [33]. In addition, the target
tissues for a DMD drug are the muscles throughout the whole body,
which requires more drug than a single tissue type. We expect that
large and repeated doses of PMO, as used in mouse and dogs, will be
required in order to attain therapeutic effects for DMD patients. If so,
the cost of a PMO drug for life-long treatment will probably be
prohibitive for many patients.
The second problem with PMOs is the large variability in exon-
skipping effect among muscle types and within a speciﬁc muscle.
Some skeletal muscles responded to PMO better than the others, as
shown in both the mouse and dog studies. Even within these
responsive muscles, dystrophin was not uniformly expressed, varying
frommuscle section to section and within a section, with detection of
patches of dystrophin-positive ﬁbers and patches of dystrophin-
negative ﬁbers [14,15,17]. Thismay be because only leakymuscle cells
can take in PMO. Therefore, PMO's efﬁcacy in humans will depend on
the number of leaky muscle ﬁbers and howwell these leaky ﬁbers can
carry out the necessary biological processes to restore the dystrophin
and its associated protein complex.
The last problem but not the least important is that PMO has
shown very little efﬁcacy in the hearts of the mouse and dog models
unless a huge dose is used. The PMOE23 restored about 5% and 30% of
wild-type level of cardiac dystrophin at 300 and 3000 mg/kg dose,
respectively [30]; at a dose of 3000 mg/kg, 0.3% of the organism is
PMO by mass and such an extreme treatment would be unsustainable
long term. Increased skeletal musclemobility with the PMO treatment
may increase workload for the hearts of the patients [34,35]. ClinicallyFig. 2. Comparison of exon-skipping efﬁcacy of PMOE23 and PPMOE23 inmdxmice and in wi
400 mg/kg (right) or the (RXRRBR)2-PMO23 conjugate at 12 mg/kg (left) through tail veins
and stained for dystrophin according to an immunoﬂuorescent method described elsewhere
kg or the (RXRRBR)2-PMO23 conjugate at 20 mg/kg once a week for 6 weeks through tail ve
PCR analysis according to amethod described elsewhere [27]. Threemice were used for each
The top and bottom bands in the lanes represent the unskipped and skipped (removal of erelevant cardiomyopathy is observed in 95% of DMD patients, and 20–
30% of the deaths are primarily attributable to heart disease [36].
Therefore, a safe and effective delivery strategy is needed that will
reduce dose level and dose frequency, will deliver the PMO to non-
leaky muscle ﬁbers, and will deliver the PMO to the heart.
4.2. PPMO: promise and challenge for DMD
PPMOs are much more effective than PMOs because of the ability
of CPPs to increase the volume of distribution of PMOs [28] to whole-
body muscles and to facilitate the internalization of PMO through an
active process, unlike the passive diffusion process for PMO. PPMOs
are internalized by nearly all muscle cells; their delivery is not limited
to leaky muscle cells as are PMOs. With 2 µg of PMO or PPMO injected
intramuscularly to the TA muscles ofmdxmice, 14% of the ﬁbers were
dystrophin-positive after PMO treatment versus the 85% of ﬁbers that
were positive after PPMO treatment [17]. This ﬁnding is veriﬁed by a
study using systemic tail vein injection [37,38]. A single 12 mg/kg
injection of the (RXRRBR)2-PMOE23 resulted in restoration of
dystrophin in nearly 100% of the ﬁbers of the quadriceps muscles,
while only a small percentage of dystrophin-positive ﬁbers were
detected after administration of the PMOE23 at 400 mg/kg (Fig. 2A).
Uptake of PPMO does not depend on the leakiness of ﬁbers, as
demonstrated by the healthymonkey study of AVI 5038 [20] as well as
by the study shown in Fig. 2B [37,38], comparing the efﬁcacy of PMO
and PPMO in wild-type C57 mice. With 6 weekly IV injections of
20 mg/kg each, N95% exon-skipped RNA transcript was detected in
the skeletal muscles after PPMO treatment while very little exon-
skipped transcript was detected for the PMO treatment even at a 40-
fold higher dose (6 × 800 mg/kg) (Fig. 2B).ld-type C57mice. (A) Seven- to eight-week-oldmdxmice were injected with PMOE23 at
and the mice were sacriﬁced 1 week after the injection. The quadriceps were sectioned
[14] (B). Twelve-week-old wild-type C57 mice were injected with PMOE23 at 800 mg/
ins and the mice were sacriﬁced 1 week after the injection. Muscles were taken for RT-
treatment. Each lane represents RNA sample isolated from amuscle of individual mouse.
xon 23) transcripts, respectively.
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dystrophin expression in the hearts of mdx mice, with nearly 100%
of themdxmuscle ﬁbers immunostaining positive for dystrophin with
the treatment at 30 mg/kg [17]. A single tail vein injection at 15 mg/
kg of the (RXRRBR)2-PMOE23 resulted in cardiac dystrophin
restoration at 11% of wild-type level as measured by Western blot
and nearly 100% of the cardiac myocytes of the mdx mice
immunostained positive for dystrophin [37–39]. Improvement in
heart function with the PPMO treatment has been demonstrated
[17,26]. These studies indicate that PPMOs can be used at a much
lower dose than PMOs and can achieve more widespread exon
skipping throughout the whole body's muscles including the heart.
The toxicity of current PPMO chemistry poses a challenge for
determination of an effective and safe dose regimen in human. The
nature of the toxicity is not well understood. Likely it is due to the
cationic nature of the peptide. There seems to be a dose threshold for
the toxicity, and the threshold level depends on the amino acid
composition of a peptide. Below the threshold, toxicity was not
observed. Above it, the severity of toxicity is dose-dependent. Toxicity
includes lethargy, weight loss [28] and tubular degeneration in kidney
[20]. The severity of toxicity is also dependent on the dose frequency.
Animals can tolerate doses and recover better if infrequent dose
schedules are followed. For a given peptide, the threshold level varies
among the animal species, with monkeys seeming more sensitive to
the PPMO-related toxicity than mice. (RXRRBR)2-PMOE23 exhibited
no toxic effect in kidneys at either 20 mg/kg weekly injection to the
wild-type mice for 6 weeks (data not shown) or 30 mg/kg biweekly
injection to mdx mice for 3 months [17]. However, the same peptide
conjugated to the PMO targeted to human exon 50, AVI-5038, was
found to cause mild tubular degeneration in the kidneys of monkeys
at 9 mg/kg weekly injections for 4 weeks [20]. This indicates that
PPMO toxicity is observed at lower dose level in monkeys than in
mice, although the change in the PMO sequence means the antisense
component might contribute to toxicity in the monkey. For instance,
skipping exon 23 does not frameshift downstream dystrophin, while
skipping exon 50 in healthy animals does; however, 4 weeks is not
enough time to deplete all the preexisting dystrophin, and loss of
dystrophin would not be expected to severely damage kidney. In
addition, if there is a sequence related off-target effect, it will
contribute to the observed toxicity [40].
The efﬁcacious dose of a PPMO is also likely scaled by body weight
from mouse to monkey to human. The PPMOE23 at 20 mg/kg induced
nearly 100%exon-skipped transcripts in thequadriceps anddiaphragms
ofwild-typemice. Themonkey equivalent dose scaled by surface area at
3 mg/kg of AVI-5038 had little exon-skipping effect in those muscles
and a higher dose at 9 mg/kg caused 25–40% exon-skipped transcript in
thosemuscles of monkeys [20]. Of course, the observation heremay not
be determined solely by dose scaling but also inﬂuenced by the exon-
skipping efﬁciency of the PMO; this in turn be affected by the
mechanism and regulation of pre-mRNA processing of the individual
targeted exon, which may vary with the species.
In conclusion, the PPMOs have potential as DMD therapeutics. One
advantage for PPMODMD therapeutics is the longhalf-life of dystrophin
and long tissue residence time of PPMOs [37–39]. Restoration of
dystrophin in themajority ofmuscleﬁbers at the intensity of 20%ofwild
type will signiﬁcantly reduce the DMD disease pathology [9]. These
factors permit an infrequent dosing schedule to minimize toxicity in
patients. Success will depend on well-designed preclinical studies to
address the relationship between dose regimens, route, and rate of drug
administration, to predict exon-skipping efﬁcacy/toxicity across species
and to plan efﬁcient yet safe dose escalation in patients.
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